Flag of the European Union EU Clinical Trials Register Help

Clinical trials for this compound

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    371 result(s) found for: this compound. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-002280-14 Sponsor Protocol Number: L00006 CP 403 3A Start Date*: 2008-07-18
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ...
    Medical condition: The Active substance of Osteopor is Ossein Hydroxyapatite. Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006956 Calcium deficiency LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002317-40 Sponsor Protocol Number: 280210BS Start Date*: 2008-10-17
    Sponsor Name:Perrigo Israel Pharmaceuticals Ltd.
    Full Title: A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with ps...
    Medical condition: Chronic plaque type psoriasis of mild to moderate severity, at least one plaque with a treatment area of approximately 25 - 50 cm2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002098-11 Sponsor Protocol Number: RC 30\07 Start Date*: 2009-06-25
    Sponsor Name:ISTITUTO PER L'INFANZIA BURLO GAROFOLO
    Full Title: Randomized Controlled Trial on the effectiveness of ketorolac and tramadole in not compound fractures of child.
    Medical condition: Not compound fractures in childhood.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017322 Fractures HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020973-18 Sponsor Protocol Number: L00006CP405 Start Date*: 2011-03-01
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: “Effect of treatment with ossein-hydroxyapatite compound on the time of fracture-healing”. A prospective, multicenter, double-blind, randomised, placebo controlled clinical trial.
    Medical condition: Wrist fracture
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10061959 Fracture treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-003811-13 Sponsor Protocol Number: N14SNS Start Date*: 2016-06-16
    Sponsor Name:Antoni van Leeuwenhoek - Netherlands Cancer Institute
    Full Title: Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study
    Medical condition: Colorectal cancer and non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001966-40 Sponsor Protocol Number: CD001 Start Date*: 2014-01-27
    Sponsor Name:Companion Diagnostics BV
    Full Title: A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify an...
    Medical condition: Hypoactive Sexual Desire Disorder/SSRI-induced sexual dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10040470 Sexual desire disorders HLT
    14.1 100000004873 10020933 Hypoactive sexual desire disorder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001104-37 Sponsor Protocol Number: ME/2011/3709 Start Date*: 2014-10-06
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia
    Medical condition: Addison's disease and Congenital Adrenal Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004848 10011195 Cortisol LLT
    17.0 100000004848 10020518 Hydrocortisone LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-000794-31 Sponsor Protocol Number: October2011,version5 Start Date*: 2011-06-15
    Sponsor Name:Dept. of Pharmacology
    Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018450-12 Sponsor Protocol Number: 706079098 Start Date*: 2010-08-18
    Sponsor Name:Agneta Blanck Olerup
    Full Title: Optimising pain control after caesarean section - an evaluation if oxycodone can replace morphine and low potency opioids postoperatively.
    Medical condition: Pain management after elective cesarean section.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036276 Postoperative analgesia LLT
    Population Age: Newborns, Under 18, Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000864-82 Sponsor Protocol Number: hydrocortisone Start Date*: 2011-12-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A randomized double blind cross-over study of the effects of low dose and high dose hydrocortisone replacement therapy on cognition, quality of life, metabolic profile and somatosensation in patien...
    Medical condition: Secondary adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10020518 Hydrocortisone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014534-15 Sponsor Protocol Number: NACIPP Start Date*: 2009-10-01
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFECT OF ACUTE ADMINISTRATION OF N-ACETYLCYSTEINE ON BLOOD PRESSURE OF PULMONARY ARTERIAL IN PRIMARY PULMONARY HYPERTENSION.
    Medical condition: PRIMARY PULMONARY HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001258-82 Sponsor Protocol Number: CFTRcysta1 Start Date*: 2013-09-12
    Sponsor Name:European Institute for Cystic Fibrosis Research (IERFC)
    Full Title: A phase II pilot clinical study of experimental research to evaluate the functional rescue of CFTR protein through proteostasis regulators
    Medical condition: Cystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutations
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003898-26 Sponsor Protocol Number: 516-007 Start Date*: 2019-12-23
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS
    Medical condition: Cancer/oncology
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004705-59 Sponsor Protocol Number: 406201215432 Start Date*: 2013-12-17
    Sponsor Name:Hôpital Erasme, ULB
    Full Title: Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed b...
    Medical condition: Newly diagnosed glioblastoma (primary highly malignant brain cancer) patients Under treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000387-14 Sponsor Protocol Number: RM-493-014 Start Date*: 2017-05-24
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000217-35 Sponsor Protocol Number: EpSSG RMS 2005 Start Date*: Information not available in EudraCT
    Sponsor Name:Rikshospitalet-Radiumhospitalet HF
    Full Title: EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma
    Medical condition: Rhabdomyosarkom (RMS) er en kreftform utgående fra muskelvev. RMS kan oppstå hvor som helst i kroppen og rammer folk i alle aldre. Behandlingen av RMS består av cellegift, operasjon og/eller strål...
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Ongoing) NL (Completed) BE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004903-20 Sponsor Protocol Number: ABR-38376 Start Date*: 2012-05-09
    Sponsor Name:
    Full Title: Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial
    Medical condition: Patients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC) • with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR • who...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003424-31 Sponsor Protocol Number: I4V-MC-JAGA Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis
    Medical condition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-000129-19 Sponsor Protocol Number: NPY Start Date*: 2015-08-28
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: A randomized , double-blind, placebo-controlled study of antidepressant effects of the endogen compound neuropeptide y (NPY) in patients suffering from major depressive disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001307-68 Sponsor Protocol Number: 68Ga-PSMA-GLIOMI-2016 Start Date*: 2017-11-07
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: ¿THE NOVEL 68Ga-PSMA THERANOSTIC PET/CT COMPOUND FOR FUNCTIONAL IMAGING OF GLIOMA¿ "IMPIEGO DELL¿INNOVATIVO TRACCIANTE TERANOSTICO 68Ga-PSMA PER L¿IMAGING FUNZIONALE PET/TC DEL GLIOMA "
    Medical condition: Suspicion of glioma on the basis of clinical and RM data, where histological confirmation is provided, as is the normal care pathway.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 19:13:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA